Pancreatic Cancer Therapy Market Report by Trends, Drivers, and Challenges - 2025

The global market for pancreatic cancer therapies is projected to grow significantly, reaching approximately US$ 4,056.4 million by 2025, up from US$ 2,011.2 million in 2017. This growth represents a compound annual growth rate (CAGR) of 8.1% from 2018 to 2025.

The expansion of the pancreatic cancer therapy market can be largely attributed to the increasing number of therapies being introduced. The ongoing development of innovative drugs is expected to be a key driver for market growth. For example, in October 2015, the FDA granted approval for Onivyde, a drug developed by Merrimack Pharmaceuticals, Inc., which is utilized as part of the treatment regimen for advanced pancreatic cancer.

Common side effects associated with chemotherapy include symptoms such as diarrhea, abdominal cramping, fatigue, loss of appetite, and alterations in taste. Chemotherapy drugs are designed to target rapidly dividing cancer cells; however, they also affect normal, healthy cells throughout the body. This can lead to adverse effects on blood-forming cells in the bone marrow, hair follicles, and cells in the mouth, digestive tract, and reproductive system. Currently available treatment options for pancreatic cancer primarily extend patients' lives by only a few months, highlighting the urgent need for more effective drugs that can enhance the efficacy of existing chemotherapy regimens.

Combining two or more chemotherapy agents is a promising strategy to improve treatment outcomes and offers potential benefits in managing the disease.

The global pancreatic cancer therapy market is categorized based on the type of cancer into two main segments: endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment dominated the market, holding the largest share. This segment is anticipated to experience the fastest growth in the coming years, as exocrine pancreatic cancer is the more prevalent type, resulting in a larger patient population during the forecast period.

Additionally, the market is segmented by therapy type into biologic therapies, chemotherapy, and other therapies. In 2017, the biologic therapy segment accounted for the largest share of the market. This segment is expected to witness the most rapid growth in the near future, driven by the increasing number of novel immunotherapies and targeted cell therapies that offer treatment options with fewer severe side effects and numerous therapeutic advantages compared to traditional chemotherapy.

Key sources of information for the pancreatic cancer therapy market analysis include reputable organizations such as the World Health Organization (WHO), American Society of Clinical Oncology, Pancreatic Cancer Action Network, National Institutes of Health, National Cancer Institute, Scientific American, American Cancer Society, and Pancreatic Cancer Research.

In conclusion, the pancreatic cancer therapy market is on a growth trajectory, driven by the introduction of new therapies and the need for more effective treatment options. The focus on biologic therapies and combination treatments is expected to play a crucial role in improving patient outcomes and extending survival rates for those diagnosed with this challenging disease.